KODIAK SCIENCES INC (KOD)

US50015M1099 - Common Stock

3.3  -0.44 (-11.76%)

After market: 3.2981 0 (-0.06%)

News Image
4 days ago - BusinessInsider

KOD Stock Earnings: Kodiak Sciences Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kodiak Sciences (NASDAQ:KOD) just reported results for the first quarter of 202...

News Image
4 days ago - InvestorPlace

KOD Stock Earnings: Kodiak Sciences Beats EPS for Q1 2024

KOD stock results show that Kodiak Sciences beat analyst estimates for earnings per share the first quarter of 2024.

News Image
4 days ago - Kodiak Sciences Inc.

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. "We continue...

News Image
6 days ago - Kodiak Sciences Inc.

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

News Image
17 days ago - Kodiak Sciences Inc.

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile....

News Image
2 months ago - InvestorPlace

KOD Stock Earnings: Kodiak Sciences Misses EPS for Q4 2023

KOD stock results show that Kodiak Sciences missed analyst estimates for earnings per share the fourth quarter of 2023.

News Image
2 months ago - BusinessInsider

KOD Stock Earnings: Kodiak Sciences Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kodiak Sciences (NASDAQ:KOD) just reported results for the fourth quarter of 20...

News Image
2 months ago - Kodiak Sciences Inc.

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection...

News Image
2 months ago - Kodiak Sciences Inc.

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

News Image
4 months ago - Kodiak Sciences Inc.

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

News Image
5 months ago - Kodiak Sciences Inc.

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

News Image
6 months ago - Kodiak Sciences Inc.

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

News Image
6 months ago - Kodiak Sciences Inc.

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023. "We have...

News Image
7 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the trading week right with a breakdown of the biggest pre-market stock movers worth noting on Monday morning!

News Image
7 months ago - Kodiak Sciences Inc.

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

/PRNewswire/ -- Kodiak Sciences Inc (NASDAQ: KOD) today announced that data from tarcocimab tedromer will be presented during the annual meeting of the...

News Image
7 months ago - Kodiak Sciences Inc.

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

News Image
8 months ago - Kodiak Sciences Inc.

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

News Image
9 months ago - Kodiak Sciences Inc.

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Tarcocimab demonstrated strong durability, matched efficacy and comparable safety versus aflibercept in a head-to-head comparative pivotal trial over one-year...

News Image
9 months ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. ("Kodiak" or the "Company") (NASDAQ: KOD). Such investors...

News Image
9 months ago - Seeking Alpha

Kodiak Sciences CMO resigns in wake of failed studies for lead drug (KOD)

Kodiak Sciences' (KOD) chief medical officer is stepping down from his position in the wake of two failed Phase 3 studies for the company’s lead drug candidate. Read more here.